A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of MEGF0444A, a Human IgG1 Antibody, in Combination With Bevacizumab and Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors

Trial Profile

A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of MEGF0444A, a Human IgG1 Antibody, in Combination With Bevacizumab and Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2016

At a glance

  • Drugs Parsatuzumab (Primary) ; Bevacizumab; Paclitaxel
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 26 Oct 2012 Planned End Date changed from 1 May 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov record.
    • 13 Oct 2011 Planned number of patients changed from 36 to 72; according to a Roche presentation, the trial has been expanded to include a cohort of patients with renal cell carcinoma.
    • 03 Mar 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top